Zevra Therapeutics (NASDAQ:ZVRA) & Reliv’ International (OTCMKTS:RELV) Head-To-Head Review

Reliv’ International (OTCMKTS:RELV) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Volatility and Risk

Reliv’ International has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Reliv’ International and Zevra Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reliv’ International	0	0	0	0	0.00
Zevra Therapeutics	0	2	9	0	2.82

Zevra Therapeutics has a consensus target price of $27.14, indicating a potential upside of 139.36%. Given Zevra Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Reliv’ International.

Valuation and Earnings

This table compares Reliv’ International and Zevra Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reliv’ International	$35.06 million	0.09	-$440,000.00	($0.09)	-20.33
Zevra Therapeutics	$106.47 million	6.32	$83.23 million	$0.92	12.33

Zevra Therapeutics has higher revenue and earnings than Reliv’ International. Reliv’ International is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.7% of Reliv’ International shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 30.0% of Reliv’ International shares are owned by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Reliv’ International and Zevra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Reliv’ International	-0.61%	-1.89%	-1.31%
Zevra Therapeutics	42.82%	54.54%	34.15%

Summary

Zevra Therapeutics beats Reliv’ International on 13 of the 14 factors compared between the two stocks.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.

About Zevra Therapeutics

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.